Related Experiment Video
Updated: May 15, 2026

Isolation of Primary Patient-specific Aortic Smooth Muscle Cells and Semiquantitative Real-time Contraction Measurements In Vitro
Published on: February 15, 2022
Telmisartan modulates mitochondrial function in vascular smooth muscle cells
Kiyo Takeuchi1, Koichi Yamamoto, Mitsuru Ohishi
1Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Abstract:
The development of atherosclerosis is associated with disturbances in mitochondrial function that impair effective adenosine triphosphate (ATP) production, increase generation of superoxide and induce subsequent apoptosis in vascular smooth muscle cells (VSMCs). As peroxisome proliferator-activated receptor gamma (PPARγ) has a potentially important role in the regulation of mitochondrial metabolism, we studied effects of the partial PPARγ agonist and angiotensin receptor blocker telmisartan, on mitochondria-related cellular responses in VSMC. In human VSMC, telmisartan increased ATP levels and activation of mitochondrial complex II, succinate dehydrogenase, reduced the release of H2O2 and attenuated H2O2-induced increases in caspase 3/7 activity, a marker of cellular apoptosis. Eprosartan, an angiotensin II receptor blocker that lacks the ability to activate PPARγ, had no effect on these mitochondria-related cellular responses in VSMC. Studies in PPARγ-deficient VSMC revealed that the effects of telmisartan on mitochondrial function were largely independent of PPARγ although the presence of PPARγ modulated effects of telmisartan on H2O2 levels. These findings demonstrate that telmisartan can have significant effects on mitochondrial metabolism in VSMC that are potentially relevant to the pathogenesis of cardiovascular disease and that involve more than just angiotensin receptor blockade and activation of PPARγ.
Insights
Telmisartan improves mitochondrial function in vascular smooth muscle cells (VSMCs) by enhancing adenosine triphosphate (ATP) production and reducing apoptosis. These effects on mitochondria are key to understanding cardiovascular disease pathogenesis.
Area of Science:
- Cardiovascular Biology
- Mitochondrial Medicine
- Pharmacology
Background:
- Atherosclerosis involves mitochondrial dysfunction in vascular smooth muscle cells (VSMCs), leading to impaired ATP production, increased superoxide generation, and apoptosis.
- Peroxisome proliferator-activated receptor gamma (PPARγ) plays a role in regulating mitochondrial metabolism.
Purpose of the Study:
- To investigate the effects of telmisartan, a partial PPARγ agonist and angiotensin receptor blocker, on mitochondria-related cellular responses in VSMCs.
- To determine if telmisartan's effects on mitochondrial function are mediated by PPARγ activation.
Main Methods:
- Human VSMCs were treated with telmisartan or eprosartan.
- Mitochondrial function markers, including ATP levels, mitochondrial complex II activity, and hydrogen peroxide (H2O2) release, were assessed.
- Apoptosis was measured by caspase 3/7 activity.
- Experiments were conducted in both normal and PPARγ-deficient VSMCs.
Main Results:
- Telmisartan increased ATP levels and mitochondrial complex II activation in VSMCs.
- Telmisartan reduced H2O2 release and attenuated H2O2-induced apoptosis.
- Eprosartan, lacking PPARγ activation, had no significant effects.
- Telmisartan's effects on mitochondrial function were largely independent of PPARγ, though PPARγ modulated H2O2 levels.
Conclusions:
- Telmisartan significantly impacts mitochondrial metabolism in VSMCs, independent of solely acting through angiotensin receptor blockade or PPARγ activation.
- These findings suggest telmisartan's potential relevance in cardiovascular disease pathogenesis due to its beneficial effects on mitochondrial function.
Related Concept Videos
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Mitochondrial Membranes
Antihypertensive Drugs: Vasodilators
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antihypertensive Drugs: Direct Renin Inhibitors